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Abstract
Objective—Abnormal eye gaze is a hallmark characteristic of autism spectrum disorder (ASD), 
and numerous studies have identified abnormal attention patterns in ASD. The primary aim of the 
present study was to create an objective, eye tracking-based autism risk index.
Method—In initial and replication studies, children were recruited after referral for 
comprehensive multidisciplinary evaluation of ASD and subsequently grouped by clinical 
consensus diagnosis (ASD n=25/15, non-ASD n=20/19 for initial/replication samples). Remote 
eye tracking was blinded to diagnosis and included multiple stimuli. Dwell times were recorded to 
each a priori-defined region-of-interest (ROI) and averaged across ROIs to create an autism risk 
index. Receiver operating characteristic curve analyses examined classification accuracy. 
Correlations with clinical measures evaluated whether the autism risk index was associated with 
autism symptom severity independent of language ability.
Results—In both samples, the autism risk index had high diagnostic accuracy (area under the 
curve [AUC]=.91 and .85, 95%CIs=.81–.98 and .71–.96), was strongly associated with Autism 
Diagnostic Observation Schedule–Second Edition (ADOS-2) severity scores (r=.58 and .59, p<.
001), and not significantly correlated with language ability (r≤|−.28|, p>.095).
Conclusion—The autism risk index may be a useful quantitative and objective measure of risk 
for autism in at-risk settings. Future research in larger samples is needed to cross-validate these 
findings. If a validated scale for clinical use, this measure could inform clinical judgment 
regarding ASD diagnosis and track symptom improvements.
Keywords
autism spectrum disorder; remote eye tracking; objective measure; autism symptoms; risk
INTRODUCTION
Deficits in eye gaze are a hallmark feature of autism spectrum disorder (ASD)1, 2 and are 
included in gold-standard diagnostic instruments.3, 4 More than a decade of research into 
abnormalities of eye gaze has confirmed social attention deficits as a key feature of ASD.5–9 
Across studies, diverse stimulus paradigms have elicited social attention abnormalities, 
ranging from decreased fixation to others’ eyes5 and social scenes10 as early as 6 months of 
age, to gaze abnormalities during dyadic or joint attention bids in preschoolers11 and older 
children,12 to aberrant gaze toward dynamic social stimuli in older high-functioning 
individuals.13 Subtler, but identifiable, gaze abnormalities have also been seen in family 
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members with the broad autism phenotype.14 This implies that eye gaze patterns, 
particularly those based on dynamic temporal analysis,15 may be a promising objective risk 
marker of ASD as well as a quantitative measure of autism symptoms spanning the full 
continuum of behavior. Two recent studies provided some support for the potential 
discriminative value of eye gaze tracking.16, 17 In these studies, individual stimulus 
paradigms had modest but potentially informative discriminative value (areas under the 
curve [AUC] =.71–.72) in separating ASD and developmental delay17 or healthy control 
cases.16 However, no published studies have evaluated whether aggregating eye tracking 
metrics across stimulus paradigms might show sufficient validity (AUC≥.80) to inform 
clinical judgment by accurately discriminating ASD from a clinically realistic comparison 
group.
Beyond accurate discrimination, objective measures of autism symptom severity are needed 
to provide quantitative assessments for tracking intervention effectiveness. At present, 
autism symptoms are measured using direct clinical observation, parent interview, and/or 
parent-report.18, 19 These methods are heavily influenced by subjective perceptions, and 
both parent-interview and clinician observation measures also require substantial training 
with ongoing inter-rater reliability checks. Parent-report questionnaires are easier to obtain 
and have shown validity for separating ASD and non-ASD,20–23 but they are heavily 
influenced by rater biases (e.g. halo or contrast effects), measurement context, and are often 
conflated with other psychopathology symptoms,24, 25 reducing their effectiveness in 
clinically challenging samples. Lastly, none of the current diagnostic approaches readily 
produce interval-scale measurements that yield high reliability across the full range of 
behavior in neurotypical and ASD-affected individuals. This is true even for the Social 
Responsiveness Scale (SRS), where a floor effect is observed when converting low raw 
scores to standard scores.26 Development of quantitative, interval-scale measures of autism 
symptoms, including measures of the core symptom domains of social communication/
interaction (SCI) and restricted/repetitive behavior (RRB), would represent a major step 
forward in the technology used to capture autism symptom levels and risk for categorical 
ASD diagnosis.
Remote eye tracking is a promising technology for development as an objective measure of 
autism. In addition to literature support for gaze abnormalities in ASD, remote eye tracking 
is easier to calibrate and collect in young or severely impaired children relative to traditional 
headgear-based eye tracking methods and other methods that require significant preparation 
(e.g. electroencephalogram [EEG]/event-related potential [ERP]), physical restrictions (e.g. 
magnetic resonance imaging [MRI]/magnetoencephalography [MEG]), and possibly 
sedation (e.g MRI). Young children are familiar with watching TV, and their attention is 
often sufficiently captured over short intervals. When attention capture is more challenging, 
visual stimuli can be repeated and interspersed around short breaks, with multiple stimuli 
used to further enhance novelty and attention. Use of multiple stimulus paradigms also 
permits capture of different aspects of attention, including attention to socially appropriate 
targets and non-social/distractor targets. Relative to the massive literature examining social 
attention in ASD, very little research has focused on abnormalities of attention to nonsocial/
distractor stimuli.27 Inappropriate attention to nonsocial stimuli is frequently observed 
clinically and is an important part of the description of RRB symptoms.28 Supporting this 
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observation, Sasson et al.27 recently demonstrated that attention to objects vs. people and 
attention to high vs. low autism-interest items were associated with greater RRB symptoms. 
This study suggests that it may be possible to identify characteristic gaze patterns to 
nonsocial stimuli that more strongly associate with RRB than SCI symptoms. Visual 
attention paradigms can readily integrate both social and nonsocial/distractor targets without 
adding time or reducing participant engagement.
The primary aim of the present research was to develop and replicate an objective measure 
of autism symptom level based on eye gaze tracking to social and nonsocial stimuli, 
hereafter referred to as the “autism risk index” (ARI). We hypothesized that ASD-affected 
children would show less attention to social and greater attention to nonsocial targets than 
children without an ASD diagnosis but with other developmental neuropsychiatric concerns 
(non-ASD). Based on this expectation, the ARI was created by averaging dwell times to a 
priori social and nonsocial target regions of interest. In initial and replication samples, the 
ARI was expected to show strong discrimination (AUC≥.80) of ASD and non-ASD cases 
and be significantly related to overall autism symptom severity but not language measures.
METHOD
Samples
Participants were children, ages 3.0 to 8.11, referred to a tertiary care multidisciplinary ASD 
specialty clinic. Referrals were made by local pediatricians, following autism screening, if 
there was clinical concern of social deficits or ASD, or if parents or teachers had concerns. 
Patients were consecutively recruited at the time of the diagnostic evaluation visit (initial 
study - July 2014 and June 2015; replication study - August 2015–November 2015). Gaze 
data were collected prior to the consensus diagnosis team meeting, and the research team 
was blinded to participant diagnosis. Procedures of this research were reviewed and 
approved by the Cleveland Clinic institutional review board (IRB).
Eye Tracking
Eye tracking data were collected in a quiet room adjacent to the diagnostic clinic. Data were 
recorded at using an SMI remote eye tracker (initial study: Red-m at 120Hz, replication 
study: Red250 at 60Hz) attached to the frame of a 1280 horizontal X 1024 vertical 19-inch 
LCD stimulus presentation monitor. Spatial resolution of these systems was 0.1°, and 
average gaze position accuracies were 0.5°. The system allows for head movement (32 × 21 
× 25cm for Red-m and 32 × 21 × 30 for Red250) at a maximum distance of 75cm. In the 
initial study, a 3- or 5-point calibration was obtained prior to the experiment. In the 
replication study, an initial and four additional 5-point calibrations were obtained at fixed 
times throughout the experiment (see Supplement 1, available online). Proportion net dwell 
time to each ROI was derived using SMI BeGaze software. Dwell time was defined as the 
sum of all sample durations (all fixations and saccades) falling within the ROI divided by 
the total stimulus time.
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Visual Stimulus Battery
Stimuli were presented using SMI Experiment Center, and stimuli for the initial study were 
selected to represent multiple distinct types previously used in the eye gaze literature, 
including static facial affect, biological vs. non-biological pairings, and dynamic/naturalistic 
scenes. Figures S1–S2 (available online) present example stimuli created for the initial and 
replication studies, and Tables S1–S2 (available online) list all stimuli and ROIs. Stimuli 
were presented in a single order, intermixed with attention-grabbing stimuli, gaze 
recalibration, and receptive language stimuli, and other stimuli not considered for the 
present paper. Total experiment time was approximately 7 minutes for both the initial and 
replication studies.
For the initial study, a priori ROIs were identified by the first author, who did not participate 
in data collection or diagnostic evaluations. ROIs were drawn to capture important social 
(faces, key body movements) and nonsocial target stimulus elements (distractors). A priori 
ROIs were further restricted to key time points within each stimulus based on a socially 
relevant action. When relevant, a priori ROIs were also designated across the total stimulus 
period to capture basic attention to social versus nonsocial elements. For example, in 
dynamic joint attention stimuli, a temporal ROI evaluated gaze to the most relevant social 
action (e.g., gaze-and-point to a target), but the total stimulus period was also examined to 
capture overall attention to the social (e.g., face) and nonsocial information (e.g., clock). A 
total of 68 a priori ROIs were identified, including 51 social and 17 nonsocial ROIs.
Replication study stimuli were chosen based on results from the initial study. Specifically, 
the replication study focused on stimuli showing the strongest validity in the initial study—
joint attention and child joke stimuli—and enriched for nonsocial ROIs. New stimuli were 
created to mimic videos used in the initial study. A total of 42 a priori ROIs were identified, 
including 19 social and 23 non-social ROIs.
For both studies, all ROIs were truly a priori. No preliminary analyses of ROI validity were 
conducted to choose ROIs and no post hoc modifications were made to ROIs to enhance 
validity.
Procedure
Eye tracking data collection followed recommendations from Sasson and Elison.9 Children 
were seated alone or in their parent’s lap approximately 65cm from the LCD display and 
viewed stimuli subtending a visual angle of 18.8°. Standard room lighting was used, and the 
room was sparse, with visual barriers used to reduce distraction. After calibration, children 
were told, “You will see some pictures and videos, pay attention, but look however you 
want.” Data for individual ROIs were excluded if proportion dwell to any location on the 
stimulus was <40%. Gaze needed to be detected on-screen ≥40% of the time and 
participants had to have at least 20 ROIs available dwell data to consider the eye tracking 
evaluation valid. A minimum tracking ratio of 40% was selected based on recommendations 
to exclude children with very low overall attention to stimuli,9 and this ratio was combined 
with a minimum number of ROI to ensure that sufficient data contributed to computation of 
the ARI.
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The same procedures were followed for the replication study with a few notable exceptions. 
First, an anonymous reviewer of an early draft of this manuscript suggested using healthy 
control participants to select ROIs. Following this suggestion, we recruited 12 healthy 
control children (ages 2–15; 4 females), and their gaze data were viewed in SMI Be Gaze 
software to identify a priori social targets (see Supplement 2, available online). Second, 
results of the initial study identified trends toward lower scores on the ARI in older 
individuals and individuals with higher tracking ratios. Additionally, inspection of healthy 
control data identified longer dwell times to social ROIs in older children and children with 
higher tracking ratios. Preliminary analyses confirmed this observation, identifying 
consistently positive small-to-medium-sized relationships between social ROI dwell times 
and age/tracking ratios. For this reason, social ROIs were residualized after regressing age 
and tracking ratio. Due to these methodological differences, the replication study should be 
considered a partial replication and extension that generalizes the approach rather than an 
exact replication.
Consensus Diagnosis
Consensus diagnosis was based on diagnostic interviews conducted by a psychologist, 
developmental and psychosocial history confirmed by the psychologist, medical history 
confirmed by a physician, cognitive testing administered by a speech language pathologist, 
and the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2) administered 
by a reliable administrator. Within two weeks of the initial visit, a multidisciplinary team 
meeting was conducted to confirm the presence/absence of DSM-5 criteria for ASD and 
document any other psychiatric diagnoses.
Clinical Measures
ADOS-2—The ADOS-2 is the gold-standard clinical observation measure used to assess 
autism symptom severity. For the present study, the ADOS-2 total, social affect subscale, 
and restricted/repetitive behavior subscale raw scores were converted to calibrated severity 
scores.29, 30
SRS-2—Parents completed the SRS-2 as part of the clinical evaluation. The SRS-2 is a 65-
item, ordinally scaled (1= “not true” to 4= “almost always true”) quantitative assessment of 
the level of autism traits. The SRS sex-adjusted total T-score has been extensively validated 
and distinguishes youth with autism from other psychiatric conditions.31, 32
Language—Receptive and expressive language was collected as part of the clinical 
evaluation using the Mullen Scales of Early Learning,33 the Clinical Evaluation of Language 
Fundamentals – Fourth Edition34 or Preschool Version – Second Edition,35 or the Preschool 
Language Scales – Fifth Edition.36 For Mullen subscales, T-scores were converted to 
standard scores (M=100, SD=15).
Child Behavior Checklist (CBCL)—Other psychopathological symptoms were 
collected using the CBCL – ages 1.5 to 5 and 6–18 parent-report versions.37 Total problems 
T-score was used to describe the sample and examine whether other psychopathology 
influences the ARI.
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Statistical Analyses
The study design and analyses followed recommendations for evaluating test validity (See 
Table S3, available online).38, 39 Univariate and bivariate distributions were examined to 
identify outliers and ensure that high leverage cases did not unduly influence relationships. 
Descriptive statistics were presented separately for patients with ASD and non-ASD patients 
to characterize the sample. Comparisons between ASD and non-ASD groups were made 
across demographic and clinical measures using independent samples t-tests or Chi-square 
statistics.
To develop the ARI, the directionality and discriminative strength of individual ROIs was 
evaluated by computing independent samples t-tests and associated effect sizes (Cohen’s d). 
The dependent variable was proportion dwell time to each ROI. ASD-affected children were 
predicted to look less at social targets and more at non-social targets. Effect sizes were 
transformed so that positive values represent differences in the predicted direction. The 
number of ROIs in the predicted direction and the number of ROIs with statistically 
significant differences in the predicted direction were compared to expected proportions (.50 
and .05, respectively) using a one-sample proportion test. After establishing the expected 
directionality for the majority of ROIs, dwell times to social and nonsocial ROIs were 
standardized using the non-ASD means and standard deviations. These standardized ROI 
scores were separately averaged to create social and nonsocial attention measures, 
respectively. Finally, the social and nonsocial attention measures were averaged (after 
reflection of the social attention index - multiplying each score by −1) to form the ARI. 
Internal consistency reliability of the social and nonsocial attention measures was computed 
using Cronbach’s α, using packets of nonsocial ROIs as items (4–7 items per packet).
Validity of the ARI was estimated using receiver operating characteristic curve analyses. 
Area under the curve (AUC) was calculated using consensus diagnosis (ASD vs. non-ASD) 
or ADOS classifications (non-spectrum vs. autism spectrum) as the state variable. To 
determine the potential incremental validity of social and non-social attention measures in 
predicting ASD, hierarchical logistic regressions were computed with social and non-social 
attention measures alternating as the predictors in steps 1 and 2. Incremental validity of the 
ARI over the SRS-2 was made using hierarchical logistic regression, with the SRS-2 entered 
in step 1 and the ARI in step 2. A significant increase in R2 from step 1 to 2 would indicate 
that the ARI improves detection of ASD diagnoses.40
Convergent validity of the ARI with clinical measures of autism symptoms was evaluated by 
computing using Spearman’s rank-order correlations between eye tracking measures and 
autism symptoms (ADOS-2 and SRS-2 scores), demographics (age and sex), and tracking 
ratio (total time-on-screen). Non-parametric (Spearman’s) partial correlations were 
computed between the ARI and language measures and CBCL behavior scores after 
accounting for ADOS-2 total calibrated severity scores.
Power to detect a significant AUC (p<.05) was computed in the initial and replication 
samples using pROC in R.41, 42 Minimum AUC of .73 and .77 were detectable with power 
(1-B)=.80 in the initial and replication samples. Group comparisons between ASD and non-
ASD cases for individual ROIs had adequate power (≥.73) for detecting large differences 
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(Cohen’s d≥.80; p<.05). Both samples also had good power (≥.77) for detecting large 
positive relationships (r≥.40) between eye tracking measures and clinical measures of autism 
symptom severity.
ROC analyses were computed using pROC,41 and non-parametric Spearman’s rank-order 
bivariate and partial correlations were implemented using the ppcor program43 in R. 
Individual ROI analyses were computed using IBM SPSS v23.0.44 In spite of strong 
directional predictions for all group differences and bivariate relationships, α=.05 two-tailed 
was used. Emphasis was placed on effect magnitude and confidence intervals, as these are 
the most crucial features for test validity. Effect sizes conventions were small (d=.20), 
medium (d=.50), and large (d=.80)45 for group comparisons. A rough guideline for 
evaluating AUC values is: <.70=poor, .70–.79=fair; .80–.89 = good; and .90 – 1.00 = 
excellent.46
RESULTS
Participant Accounting
Figure S3 (available online) describes participant inclusion/exclusion. Of the individuals 
who consented, 6 children from the initial study and 3 children from the replication study 
could not adequately attend to the stimuli at least 40% of the time (ASD n=1/2, non-ASD 
n=5/1). All individuals who could not achieve a valid administration had low language 
scores (SS<74) and/or severe autism symptom levels (ADOS-2 calibrated severity score≥7).
Sample Descriptions
Table 1 presents sample characteristics for the initial and replication studies. As expected, 
the group with ASD had higher autism symptom severity scores on the ADOS-2 and lower 
language scores. The non-ASD group had a range of psychiatric diagnoses, with one non-
ASD participant receiving no clinical diagnosis in each sample. Consistent with the at-risk, 
referred nature of these samples, there were no significant differences in SRS-2 or CBCL 
total problems scores, and high scores did not discriminate cases of ASD and non-ASD 
cases in either sample (SRS-2: AUC=.58 and .43, 95%CI=.39–.77 and.22–.66; CBCL: 
AUC=.36 and.41, 95%CIs=.18–.54 and .19–.64). Broad ranges of ADOS-2 total severity 
scores, SRS Total T-scores, and CBCL scores were observed, with near complete overlap in 
parent-reported autism traits and slightly more behavior problems in non-ASD cases (See 
Figures S4 and S5, available online). Importantly, the tracking ratio (total time-on-screen) 
did not significantly differ between patients with ASD and non-ASD patients.
Individual ROIs
Dwell time differences between participants with ASD and non-ASD participants were in 
the expected direction for the majority of ROIs (initial study: 57 of 68 [z=4.54, p<.001); 
replication study: 37 of 42 [z=4.43, p<.001]; Figure 1a and 1b) and a substantial minority 
were statistically significant in the expected direction in both samples (initial study: 19 of 68 
[z=7.05, p<.001] and replication study: 11 of 42 [z=5.67, p<.001]). Effect sizes were highly 
variable across ROIs (d=−.41–1.35). In the initial sample, 9 of the 10 largest effect sizes 
(Cohen’s d>.75) were from joint attention or child joke stimuli, supporting focus on these 
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stimuli in the replication study. Internal consistency reliability was adequate for the social 
attention measure (α=.73 and .76) and marginal to adequate for the nonsocial attention 
measure (α=.53 and .76) across the two samples.
Identification of Cases of ASD
ARI scores had limited overlap (Cohen’s d=1.15 and 1.41) and showed very good 
discrimination (AUC=.91 and .85, 95%CI=.81–.98 and .71–.96; Figure 2a and 2b) between 
non-ASD and ASD cases in initial and replication samples, respectively. Discrimination was 
also excellent for cases meeting threshold on the ADOS-2 (AUC=.90 and .86, 95%CI=.80–.
98 and .69–.98). The ARI showed substantial incremental validity over the SRS-2 Total T-
score (smallest ΔR2=.46, X2[1]=12.16, p<.001).
Correlations With Autism Symptom Severity
The ARI was strongly correlated with ADOS-2 total (r=.58 and .59, p=.001; Figure 3a and 
b) and domain severity scores (See Table S4, available online), but was not significantly 
related to age, sex, or tracking ratio (|r|≤.28, p≥.060; See Table S5, available online). After 
accounting for total autism symptom severity, ARI scores were not significantly related to 
language ability (|r|≤.28, p≥.096). A modest significant relationship with CBCL Total 
Problems scores was observed in the replication sample. However, in both samples, the 
relationship between ARI and ADOS-2 total scores remained strong after accounting for 
total behavior problems (See Table S4, available online). SRS-2 scores were not related to 
eye tracking measures. Supplement 3, Table S6 and Figures S6–S7 (available online) 
provide additional information on the discriminative value and autism symptom correlations 
for the social and nonsocial attention measures.
Combined Sample
The ARI was computed in a highly similar fashion across the initial and replication studies. 
For this reason, we also examined discrimination after combining the samples (total N=79, 
ASD n=40, non-ASD n=39). The ARI had modest overlap (Figure 4) and very good 
discrimination between patients with ASD and non-ASD (AUC=.89, 95%CI=.81–.95). The 
optimal cutpoint based on Youden’s statistic was z=.1.04, with sensitivity of .80 (95%CI=.
68–.93) and specificity of .82 (95%CI=.69–.92). False negative ASD-diagnosed children had 
lower ADOS-2 total severity scores than correctly identified patients with ASD (4.5 vs. 6.1) 
and false positive non-ASD diagnosed children had higher ADOS-2 total severity scores 
than correctly identified patients with non-ASD (4.0 vs. 2.6; F(3,72)=27.50, p<.001). There 
were no differences between identified and missed cases for receptive language or CBCL 
Total Problems (p>190). Using the combined sample, the correlation between ARI scores 
and ADOS-2 total severity scores was strong (r=.59, p<.001) and remained strong after 
adjusting for receptive language (r=.57, p<.001) or CBCL Total Problems (r=.66, p<.001).
DISCUSSION
The present investigation demonstrates the strong potential for remote eye tracking as an 
objective tool for quantifying autism risk and estimating autism symptom severity. As 
expected, individual ROIs had variable, but generally modest, levels of discrimination of 
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patients with ASD and non-ASD. In contrast, by measuring a core cognitive feature of 
autism—dysfunctional attention to social and nonsocial information—the composite ARI 
had substantial diagnostic accuracy, dramatically outperformed the SRS-2, and showed 
strong relationships with a gold-standard measure of autism symptom severity. These results 
are very promising, particularly because the current version of the ARI was conservative: all 
a priori ROIs were included regardless of direction and validity level. Enhancements to the 
present approach are possible and may increase the validity and utility of the ARI. Potential 
improvements include: continuing to focus on the highest-validity stimuli (as was done in 
the replication study), differentially weighting stimuli, adding non-redundant and more 
dynamic gaze metrics (e.g. time-to-first-fixation to target ROIs, revisits to target, saccades, 
etc.),15 and including a larger number of nonsocial target ROIs. Adding nonsocial targets 
may be particularly important for increasing the relationship between nonsocial attention 
and RRB symptoms. Even if the ARI is unchanged in future validation studies, confidence 
intervals from the combined sample suggested that diagnostic accuracy should remain in the 
good-to-excellent range. Replication of these findings is warranted and would represent a 
major step forward, as objective markers of autism are sorely needed.
The present data suggested that the ARI may have incremental validity for ASD 
identification when used in conjunction with other clinical measures. The ARI accounted for 
substantial predictive variance after accounting for the SRS-2, and relationships between the 
ARI and ADOS-2 overall severity scores were high but did not suggest redundancy. 
Additionally, missed cases had a different pattern of ADOS-2 scores than correctly 
identified cases. Future research is needed to establish precise estimates of stand-alone and 
incremental validity of the ARI for categorical ASD diagnosis.
Beyond enhancing clinical diagnosis, objective measures are needed that grade autism 
symptom severity and track symptom changes with treatment. At present, treatment-
mediated changes in autism symptoms are gauged using subjective measures, decreasing the 
reliability of treatment effect estimates. The result is inefficient evaluation of promising 
treatments. Objectively and quantitatively measuring symptom severity would facilitate 
more accurate characterization of treatment response and enhance our ability to assess 
developmental trajectories in autism symptoms. Longitudinal studies of the ARI and the 
associated social and non-social attention measures, including collection during treatment 
studies, will be needed to determine if these measures have adequate test-retest reliability 
and are sensitive to change.
Remote eye tracking-based measures have several desirable features beyond the objective 
and quantitative nature of these measurements. Administration of visual attention paradigms 
is rapid (<10 minutes), can be largely automated, requires limited technical expertise, and 
does not involve ongoing inter-rater reliability checks. Parents are also likely to have high 
acceptance of remote eye tracking as part of the clinical evaluation. The data are easily 
acquired in most children, and reduced or altered eye contact is well understood as a 
symptom of autism. In some parents, lack of an objective measure can lead to delayed or 
diminished acceptance of the clinical diagnosis. Scalable eye-tracking solutions for other 
neuropsychiatric disorders are in development or early adoption,47, 48 further supporting the 
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viability of the approach. Thus, development of an eye tracking system implementing the 
ARI described here appears feasible and potentially informative to clinical practice.
Even with these advantages, there are technical limitations that will delay immediate clinical 
adoption of remote eye-tracking as an objective measure. Hardware and software costs are 
substantial and scoring is labor intensive. Both of these limitations can be remedied in future 
work. Remote eye tracking hardware continues to decrease in cost, with less sophisticated 
models that are sufficient for collecting viewing time at $100. Validation studies will be 
needed to demonstrate that the present findings can be obtained with less sophisticated 
hardware. Similarly, clinical viability of a remote eye tracking-based measure can be 
improved by automating scoring. Automation is highly feasible and would only require add-
on software that could be updated as the paradigm is enhanced and scoring algorithms are 
refined. Future work is also needed to extend the present findings to younger patients. 
Additional breaks in testing, re-testing at a later date, and liberal use of attention-grabbing 
stimuli may be useful methods for improving the number of young and low-functioning 
children who achieve a valid evaluation.
The primary limitations of the present study were modest sample sizes for the initial and 
replication studies, lack of calibration quality measures for the initial study, and evaluations 
of test performance under high prevalence conditions. The combined sample size of the 
present study was larger than most of the recently reviewed eye tracking studies in children 
and included a developmental disability control group larger than almost all previous 
studies.8 The group with non-ASD represented a challenging comparison cohort of children 
referred for clinical evaluation of ASD, with a wide range of clinician-observed and parent-
reported autism symptoms, high levels of other behavior problems, and highly overlapping 
levels of receptive language relative to the group with ASD. In spite of its use in the 
diagnostic evaluation, several children in the group with non-ASD had ADOS-2 scores 
overlapping the group with ASD, and all but two children with non-ASD had some form of 
developmental neuropsychiatric diagnosis. The clinically realistic nature of the group with 
non-ASD indicates that diagnostic discrimination values are not likely to be inflated, an 
important consideration for test evaluation studies that has not been addressed in any 
previous eye tracking investigations. Comparisons that use healthy controls produce much 
larger effect sizes that are prone to greater shrinkage when the same test is used in clinical 
settings where other developmental conditions that could have high false positive rates are 
common.49
When considering these limitations, it is important to keep in mind that the overarching 
objective was to demonstrate the potential clinical value of combining eye tracking 
measurements into a risk index. In this light, the present results suggest substantial potential 
for the ARI to inform clinical practice. These studies should include additional clinical 
measures with better coverage of SCI and RRB domains, examine test-retest stability, 
estimate sensitivity to change, and include a healthy comparison cohort that is not used to 
identify social ROIs. A healthy comparison group will help with understanding the relative 
impairment in social and nonsocial attention in the group with non-ASD, tracking expected 
developmental changes in social and nonsocial attention, and identifying whether an 
enhanced ARI would improve screening in low base rate settings. If the above 
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recommendations are undertaken and validation of the present approach is achieved, remote 
eye tracking would be the first clinically scalable quantitative and objective measure of 
autism.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Clinical Guidance
• The ARI, based on eye gaze to social and nonsocial information, may be a 
useful quantitative and objective measure, informing clinical judgment 
regarding the presence of an ASD diagnosis in at-risk settings.
• The ARI, and by extension eye tracking-based attention measures, may 
supplement existing clinical observation measures for grading the severity of 
autism symptom levels.
• Pending acquisition of data establishing sensitivity to change, the ARI may have 
potential as an objective measure of response to pharmacological and behavioral 
intervention programs.
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Figure 1. 
Effect sizes (Cohen’s d) for individual regions-of-interests (ROI) representing the magnitude 
of group differences between cases of autism spectrum disorder (ASD) and non-ASD cases, 
separately for the initial (a) and replication studies (b).
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Figure 2. 
Areas under the curve from receiver operating characteristic curve (AUC) analysis for the 
autism risk index predicting consensus clinical autism spectrum disorder (ASD) diagnosis, 
separately for the initial (a) and replication (b) samples.
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Figure 3. 
Relationship between autism risk index scores and Autism Diagnostic Observation Schedule 
– Second Edition (ADOS-2) total calibrated severity scores, separately in the initial (a) and 
replication (b) samples.
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Figure 4. 
Autism risk index (ARI) score distributions for autism spectrum disorder (ASD) and non-
ASD cases in the combined sample.
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